Using the Totality of Evidence for Joint Clinical Assessment: Moving Beyond Single Endpoints

Under the European Health Technology Assessment Regulation (EU HTAR), Joint Clinical Assessments (JCAs) are introducing a new level of scrutiny for comparative clinical evidence. For pharmaceutical companies, success will increasingly depend not only on generating robust data, but also on demonstrating how the complete body of evidence supports the clinical value of a treatment.

This creates an important challenge. Clinical trials rarely tell a simple story through a single endpoint. Treatments may improve survival while increasing toxicity. They may delay disease progression without improving quality of life. Some patients may experience substantial benefit, while others see little change. As a result, decision-makers conducting a Joint Clinical Assessment must look beyond individual outcomes and consider the totality of evidence.

But what does that mean in practice?

What is the totality of evidence in a Joint Clinical Assessment?

In the context of a Joint Clinical Assessment, the totality of evidence refers to the combined evaluation of all clinically relevant data needed to understand the overall clinical value of a health technology.

This evidence may include:

• Efficacy outcomes, such as overall survival or progression-free survival
• Safety and tolerability data
• Health-related quality of life measures
• Patient-reported outcomes
• Functional outcomes
• Subgroup analyses
• Evidence relating to uncertainty and robustness

Rather than focusing exclusively on one endpoint, a JCA aims to understand how all relevant findings contribute to the overall assessment of comparative clinical effectiveness and safety.

This holistic perspective reflects the reality of healthcare decision-making. Patients, clinicians, regulators, and HTA bodies rarely make decisions based on a single outcome alone. They consider benefits, risks, quality of life, and treatment burden together when determining whether a therapy offers meaningful clinical value.

Why a single endpoint is rarely enough

Historically, clinical development programs have often been built around demonstrating success on a predefined primary endpoint. While this remains critical for regulatory approval, it does not necessarily provide a complete picture for health technology assessment.

Consider a treatment that improves overall survival but is associated with higher rates of severe adverse events. Alternatively, imagine a therapy that extends progression-free survival but does not improve symptoms or quality of life. In both situations, stakeholders must consider multiple dimensions simultaneously before reaching conclusions about clinical value.

Joint Clinical Assessment therefore requires interpretation, not simply endpoint reporting.

A statistically significant primary endpoint may be important, but it represents only one part of a much broader evidence package. Understanding how different outcomes interact is often essential for evaluating the true impact of a treatment on patients.

The challenge of evaluating multiple outcomes

Considering the totality of evidence sounds straightforward in theory. In practice, it can be remarkably complex.

Clinical outcomes are measured using different scales and methods. Overall survival is measured in time. Adverse events are reported as frequencies and grades. Quality of life outcomes are generated from questionnaires. Patient-reported outcomes may reflect symptoms, functioning, or treatment burden.

These outcomes cannot simply be added together.

Furthermore, different endpoints frequently point in different directions. A treatment may outperform a comparator for efficacy while performing less favorably for safety. Some benefits may be clinically meaningful while others are modest. Likewise, not all risks carry equal importance.

This creates a central challenge for Joint Clinical Assessment: how can multiple outcomes be interpreted in a consistent, transparent, and clinically meaningful manner?

Approaches to integrating the totality of evidence

Different approaches can be used to evaluate evidence across multiple endpoints.

Traditional assessments often rely heavily on expert interpretation. Clinical experts review individual outcomes, discuss trade-offs, and reach conclusions regarding the overall clinical profile of a treatment.

Structured frameworks can bring greater transparency to this process by defining which outcomes should be considered and how evidence should be interpreted. Such frameworks help ensure consistency across assessments and make decision-making more explicit.

In recent years, quantitative approaches have also emerged that seek to evaluate multiple outcomes simultaneously. These methods do not replace clinical judgment, but rather provide an additional layer of evidence that can help support decision-making.

For example, methodologies based on Generalized Pairwise Comparisons (GPC) and Net Treatment Benefit (NTB) allow multiple prioritized outcomes to be considered within a single analytical framework. By examining efficacy, safety, and other clinically relevant outcomes together, these approaches can help make treatment trade-offs more transparent and easier to communicate.

As JCA requirements evolve, interest in structured methods for integrating evidence is likely to continue growing.

The importance of patient-relevant outcomes

One of the most significant developments in modern health technology assessment is the growing emphasis on patient-relevant outcomes.

Clinical value is not determined solely by tumour response rates, laboratory measurements, or survival metrics. Patients may place equal or greater importance on aspects such as symptom control, physical functioning, independence, treatment convenience, and quality of life.

Joint Clinical Assessments are increasingly expected to reflect outcomes that matter directly to patients. This is particularly important when treatments demonstrate similar efficacy profiles but differ substantially in tolerability or impact on daily living.

A totality-of-evidence perspective helps ensure that these outcomes are not considered in isolation or treated as secondary considerations. Instead, they become part of the broader clinical narrative supporting the assessment of therapeutic value.

Moving from data to clinical interpretation

The challenge facing many sponsors is no longer generating evidence. Modern clinical trials produce large volumes of data across numerous endpoints and patient populations.

The greater challenge is translating this evidence into a coherent understanding of overall clinical value.

Joint Clinical Assessment requires decision-makers to evaluate multiple dimensions simultaneously, including efficacy, safety, quality of life, patient experience, and uncertainty. Looking at these outcomes individually remains important, but meaningful decisions depend on understanding how they fit together.

This is why the concept of totality of evidence is rapidly becoming central to JCA discussions. It provides a framework for moving beyond isolated results and towards a more comprehensive understanding of comparative clinical effectiveness and safety.

As the EU HTAR continues to reshape evidence requirements across Europe, organizations that can clearly demonstrate the totality of evidence behind their therapies will be better positioned to support transparent and robust clinical value assessments.

Frequently asked questions